Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

ClinicalTrials.gov ID: NCT00398645

Public ClinicalTrials.gov record NCT00398645. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200 mcg Twice Daily, GW685698X 200 mcg and 400 mcg Once Daily in the Morning, and GW685698X 200 mcg and 400 mcg Once Daily in the Evening Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) With Persistent Asthma

Study identification

NCT ID
NCT00398645
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
648 participants

Conditions and interventions

Conditions

Interventions

  • GW685698X 200mcg,GW685698X 200mcg and 400mcg Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 14, 2006
Primary completion
Jul 31, 2007
Completion
Aug 29, 2007
Last update posted
Jan 22, 2018

2006 – 2007

United States locations

U.S. sites
16
U.S. states
9
U.S. cities
16
Facility City State ZIP Site status
GSK Investigational Site Fullerton California 92835
GSK Investigational Site Huntington Beach California 92647
GSK Investigational Site Orange California 92868
GSK Investigational Site San Diego California 92123
GSK Investigational Site Miami Florida 33143
GSK Investigational Site North Dartmouth Massachusetts 02747
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Dayton Ohio 45406
GSK Investigational Site Sylvania Ohio 43560
GSK Investigational Site Lake Oswego Oregon 97035
GSK Investigational Site Medford Oregon 97504
GSK Investigational Site Portland Oregon 97213
GSK Investigational Site El Paso Texas 79925
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site South Burlington Vermont 05403
GSK Investigational Site Greenfield Wisconsin 53228

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00398645, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 22, 2018 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00398645 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →